{
    "clinical_study": {
        "@rank": "68899", 
        "arm_group": {
            "arm_group_label": "Ticagrelor", 
            "arm_group_type": "Experimental", 
            "description": "As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel na\u00efve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose."
        }, 
        "brief_summary": {
            "textblock": "Ticagrelor therapy has been shown to reduce the rates of cardiovascular events and all-cause\n      mortality compared to clopidogrel therapy in patients with acute coronary syndromes (ACS).\n      The benefit of this study would be to demonstrate that ticagrelor therapy is associated with\n      equivalent platelet inhibition irrespective of the disease status in patients undergoing\n      PCI."
        }, 
        "brief_title": "Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI", 
        "condition": [
            "Cardiovascular Disease", 
            "Stable Angina", 
            "Myocardial Infarction", 
            "Coronary Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Angina Pectoris", 
                "Cardiovascular Diseases", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stable Angina: Stable coronary artery disease patients with documented ischemia\n             undergoing elective PCI will be enrolled.Inclusion criteria for enrollment in the ACS\n             group with or without ST-segment elevation, requires onset of symptoms during the\n             previous 48 hours.\n\n        NSTEMI\n\n        For patients who had an ACS without ST-segment elevation (NTSEMI), two of the following\n        criteria had to be met:\n\n          -  a positive test of a biomarker (troponin I) in accordance with the universal\n             definitions indicating myocardial necrosis\n\n          -  ST-segment changes on electrocardiography, indicating ischemia that do not meet\n             criteria for STEMI.\n\n        STEMI\n\n        For patients who had an ACS with ST-segment elevation, the following two inclusion\n        criteria had to be met:\n\n          -  either persistent ST-segment elevation of at least 0.1 mV in at least two contiguous\n             leads or a new left bundle-branch block; and\n\n          -  the intention to perform primary PCI with 24 hours of symptom onset\n\n        Exclusion Criteria:\n\n          -  Patients who are on P2Y12 receptor blockers, oral anticoagulants, or GPIIb/IIIa\n             receptor blocker therapies.\n\n          -  Presence or history of any of the following: ischemic or hemorrhagic stroke;\n             transient ischemic attack (TIA); intracranial neoplasm; arteriovenous malformation,\n             or aneurysm; intracranial hemorrhage; head trauma (within 3 months of study entry)\n\n          -  History of refractory ventricular arrhythmias or an increased risk of bradycardic\n             events (eg, subjects without a pacemaker who have sick sinus syndrome, 2nd or 3rd\n             degree atrioventricular (AV) block or bradycardic-related syncope)\n\n          -  History or evidence of congestive heart failure (New York Heart Association Class III\n             or above  \u2264 6 months before screening\n\n          -  Severe hepatic impairment defined as ALT> 2.5 X ULN\n\n          -  Uncontrolled hypertension, or systolic blood pressure > 180 mmHg or diastolic blood\n             pressure > 110 mmHg at screening\n\n          -  Severely impaired renal function (glomerular filtration rate < 30 mL/minute) or on\n             dialysis\n\n          -  Platelet count <100 X103, illicit drug or alcohol abuse, prothrombin time>1.5 times\n             control, haematocrit <30%, and creatinine >2.0 mg/dl.\n\n          -  Contraindication or other reason that ticagrelor should not be administered (eg,\n             hypersensitivity, active bleeding, moderate or severe liver disease, history of\n             previous intracranial bleed, GI bleed within the past 6 months, major surgery within\n             30 days)\n\n          -  Fibrinolytic therapy in the 24 hours prior to PCI, or planned fibrinolytic treatment\n             following PCI.\n\n          -  Participation in another investigational drug or device study in the last 30\n             -Pregnancy or lactation\n\n          -  Concomitant oral or intravenous therapy (see examples below) with strong CYP3A\n             inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A\n             inducers which cannot be stopped for the course of the study\n\n          -  Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin,\n             clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir\n\n          -  Substrates with narrow therapeutic index: cyclosporine, quinidine\n\n          -  Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine\n\n          -  Any other condition which in the opinion of the investigator, may either put the\n             patient at risk or influence the result of the study (eg, cardiogenic shock or severe\n             haemodynamic instability, active cancer, risk for non-compliance, risk for being lost\n             to follow up)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012140", 
            "org_study_id": "AZSC01"
        }, 
        "intervention": {
            "arm_group_label": "Ticagrelor", 
            "intervention_name": "ticagrelor", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ticagrelor"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "kbliden@lifebridgehealth.org", 
                "last_name": "Kevin Bliden, MBA", 
                "phone": "410-601-4795"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21215"
                }, 
                "name": "Sinai Center for Thrombosis Research"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Sinai Center for Thrombosis Research", 
            "last_name": "Paul Gurbel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary end point is the pharmacodynamic (inhibition of platelet aggregation, IPA) effect of 180mg LD ticagrelor measured at 1hour post-dose by 20uM ADP-induced maximum platelet aggregation", 
            "measure": "Inhibition of platelet aggregation", 
            "safety_issue": "No", 
            "time_frame": "Pre-LD dose, 0.5, 1, 2, 3, 4-6, the next day just before and 1, 2 and 4 hours after morning maintenance dose and pre-dose and 1, 2 and 4 hours after the last study MD dose (14 +/- 3 days)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012140"
        }, 
        "responsible_party": {
            "investigator_affiliation": "LifeBridge Health", 
            "investigator_full_name": "Paul A. Gurbel", 
            "investigator_title": "Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "LifeBridge Health", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LifeBridge Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}